IPSEN (IPSEY) and Its Rivals Critical Review

IPSEN (OTCMKTS: IPSEY) is one of 24 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare IPSEN to related companies based on the strength of its institutional ownership, analyst recommendations, valuation, risk, earnings, profitability and dividends.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a breakdown of recent recommendations for IPSEN and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IPSEN 0 0 1 0 3.00
IPSEN Competitors 101 367 567 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given IPSEN’s peers higher probable upside, analysts plainly believe IPSEN has less favorable growth aspects than its peers.

Profitability

This table compares IPSEN and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IPSEN N/A N/A N/A
IPSEN Competitors -884.88% -64.84% -17.51%

Insider and Institutional Ownership

0.0% of IPSEN shares are owned by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are owned by institutional investors. 13.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares IPSEN and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IPSEN $2.27 billion $408.99 million 41.28
IPSEN Competitors $308.35 million $18.66 million -39.62

IPSEN has higher revenue and earnings than its peers. IPSEN is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Dividends

IPSEN pays an annual dividend of $0.17 per share and has a dividend yield of 0.4%. IPSEN pays out 18.3% of its earnings in the form of a dividend. As a group, “Diagnostic substances” companies pay a dividend yield of 1.3% and pay out 41.9% of their earnings in the form of a dividend.

Risk & Volatility

IPSEN has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, IPSEN’s peers have a beta of 1.44, indicating that their average stock price is 44% more volatile than the S&P 500.

Summary

IPSEN beats its peers on 8 of the 14 factors compared.

IPSEN Company Profile

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in urology ? oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology, and cardiovascular areas. Its products include Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer; and Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum toxin type A complex used to treat cervical dystonia, cerebral palsy, blepharospasms, and hemifacial spasms. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco, which are antihypertensive agents for treating hypertension; Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, BN82451, VSN16R, OPS201, OPS202, MCNA, and LX1032 drugs. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Independent Bank Co.  Announces Quarterly  Earnings Results, Beats Expectations By $0.09 EPS
Independent Bank Co. Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS
Philips  Issues Quarterly  Earnings Results, Misses Expectations By $0.05 EPS
Philips Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS
IRadimed  Set to Announce Earnings on Monday
IRadimed Set to Announce Earnings on Monday
Cantor Fitzgerald Analysts Give Heron Therapeutics  a $40.00 Price Target
Cantor Fitzgerald Analysts Give Heron Therapeutics a $40.00 Price Target
Permian Basin Royalty Trust  Stock Rating Upgraded by TheStreet
Permian Basin Royalty Trust Stock Rating Upgraded by TheStreet
Allergan  PT Set at $215.00 by Credit Suisse Group
Allergan PT Set at $215.00 by Credit Suisse Group


© 2006-2018 Ticker Report. Google+.